Form 4 for GANX Gain Therapeutics, Inc.
Accepted 2023-07-05 00:00:00 ET · period of report 2023-07-01 · accession 0001209191-23-041027 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-07-05 | 2023-07-01 | GANX | Alder Matthias | CEO, Dir | M - OptEx | — | +3,300 | 3,300 | New | — |
| D | 2023-07-05 | 2023-07-01 | GANX | Alder Matthias | CEO, Dir | M - OptEx | $0.00 | -3,300 | 9,900 | -25% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-07-01 | M | A | 3,300 | — | 3,300 | D | — | — | (F1) Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. |
| 2 | Derivative | Restricted Stock Units | 2023-07-01 | M | D | 3,300 | $0.00 | 9,900 | D | — · — to — | 3,300 Common Stock | (F1) Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. (F2) The RSUs vested 25% on July 1, 2023 and the remainder shall vest in 12 equal quarterly installments thereafter, subject to Reporting Person's continuous service through each such vesting date. |